UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 6.

Fiaschetti, G; Abela, L; Nonoguchi, N; Dubuc, A M; Remke, M; Boro, A; Grunder, E; Siler, U; Ohgaki, H; Taylor, M D; Baumgartner, M; Shalaby, T; Grotzer, M A (2014). Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma. British Journal of Cancer, 110(3):636-647.

Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, M A (2011). Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 30(25):2823-2835.

Grunder, E; D'Ambrosio, R; Fiaschetti, G; Abela, L; Arcaro, A; Zuzak, T; Ohgaki, H; Lv, S Q; Shalaby, T; Grotzer, M (2011). MicroRNA-21 suppression impedes medulloblastoma cell migration. European Journal of Cancer, 47(16):2479-2490.

Fiaschetti, G; Grotzer, M A; Shalaby, T; Castelletti, D; Arcaro, A (2011). Quassinoids: From traditional drugs to new cancer therapeutics. Current Medicinal Chemistry, 18(3):316-328.

Castelletti, D; Fiaschetti, G; Di Dato, V; Ziegler, U; Kumps, C; De Preter, K; Zollo, M; Speleman, F; Shalaby, T; De Martino, D; Berg, T; Eggert, A; Arcaro, A; Grotzer, M A (2010). The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors. Molecular Cancer Therapeutics, 9(12):3145-3157.

Grotzer, M A; Castelletti, D; Fiaschetti, G; Shalaby, T; Arcaro, A (2009). Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Current Cancer Drug Targets, 9(2):176-188.

This list was generated on Wed Jul 26 01:01:31 2017 CEST.